Delivering RNA-based therapeutics for pancreatic cancer treatment: current progress and challenges
-
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), present formidable treatment challenges owing to the intricacies of their anatomical structures and biological impediment. RNA-based therapeutics offer unprecedented potential ...
MorePancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), present formidable treatment challenges owing to the intricacies of their anatomical structures and biological impediment. RNA-based therapeutics offer unprecedented potential for PDAC treatment. This review comprehensively summarizes the latest advances in PDAC-targeted nucleic acid delivery systems, including extracellular vesicles, polymer carriers, lipid nanoparticles, viral vectors, and antibody-drug conjugates. The review highlights key features of each delivery platform, such as their structural modifications and targeting mechanisms. Additionally, it emphasizes their capacity to overcome PDAC-specific biological barriers. (e.g., blood-pancreatic barrier, immunosuppressive tumor microenvironment, dense extracellular matrix). We also outline current challenges and future directions in optimizing nucleic acid delivery for PDAC. Integrating the latest insights into PDAC biology, delivery system engineering, and nucleic acid drug development, this review provides a concise, up-to-date perspective to guide the design of effective translational strategies for PDAC therapy.
Less -
Haoyang Cong, ... Congcong Xu
-
DOI: https://doi.org/10.70401/bmeh.2026.0028 - May 20, 2026
-
This article belongs to the Special Issue Engineering RNA Delivery Technologies for Vaccine and Therapeutic Development


